9 results
(1) To asses the influence of P-gp function at the BBB on flumazenil binding to the GABAA-receptor in pharmacoresistant patients with temporal lobe epilepsy (TLE), using PET and [11C]flumazenil as a ligand and tariquidar as P-gp blocker. (2) If we…
Primary objective:To demonstrate the efficacy of dupilumab administered concomitantly with TCS through week 16 in adult patients with moderate-to-severe atopic dermatitis (AD).Secondary objectives:Evaluate long-term efficacy of dupilumab when…
The primary objective of this study is to describe the long-term safety of dupilumab in the treatment of patients with moderate to severe asthma who completed the previous asthma clinical trial, TRAVERSE-LTS12551.
Primary objective: The primary objective is to assess the long-term safety of dupilumab administered in adult patients with AD.Secondary objective:The secondary objective of the study is to assess the immunogenicity of dupilumab in adult patients…
The primary objective of the study is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with…
The objective of this study is to evaluate the efficacy and safety of upadacitinib versus dupilumab for the treatment of adult subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.
The primary objective of the present study is to establish the histological effects of givinostat versus placebo administered over 12 months. The secondary objectives of this study are the following: - To establish the macroscopic muscle effects of…
Primary objective:* To establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.Secondary objectives:* To assess the safety and tolerability of givinostat versus…
The primary objectives of the study by study part are:Part A:To determine the treatment effect of dupilumab compared with placeboin adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures…